Alternative Data for Moleculin Biotech
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 80 | Sign up | Sign up | Sign up |
| Webpage traffic | 5,000 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 99 | Sign up | Sign up | Sign up |
| Facebook Followers | 69,777 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 15 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 22,206 | Sign up | Sign up | Sign up |
| X Followers | 4,906 | Sign up | Sign up | Sign up |
| X Mentions | 19 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Linkedin Employees | 23 | Sign up | Sign up | Sign up |
About Moleculin Biotech
Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses.
| Price | $2.05 |
| Target Price | Sign up |
| Volume | 463,915 |
| Market Cap | $22M |
| Year Range | $1.96 - $20.89 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
Moleculin Biotech shares are trading higher after the company announced it is approaching the first unblinding of data in its pivotal Phase 2B/3 "MIRACLE" study of Annamycin in combination with cytarabine in AML treatment.February 17 - Benzinga |
|
Moleculin Biotech Reports Preliminary Composite Complete Remission Rate Of 40% In Phase 2B/3 Miracle Trial's First 30 Subjects Treated, With Annamycin In Combination With Cytarabine For Refractory To Or Relapsed Acute Myeloid Leukemia After Induction TherapyFebruary 17 - Benzinga |
|
Moleculin Biotech Secures Japan Patent Allowance For Liposomal Annamycin MethodFebruary 16 - Benzinga |
|
 |
Moleculin Biotech reports assessment confirms no cardiotoxicity of AnnamycinJanuary 13 - Thefly.com |
|
Moleculin Biotech says first MIRACLE trial unblinding expected in 1Q16January 12 - Thefly.com |
Pharmaceutical and Biotechnology Royalty Rates Agreements Report and Directory 2026: Insights Into 1,567 Licensing Transactions by Company A-Z, Therapeutic Area, Technology, Headline ValueMarch 12 - GlobeNewswire |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 0 | 21,000 | -21,000 | -25M | -25M | -0.680 |
| Q2 '25 | 0 | 29,000 | -29,000 | -7.6M | -7.6M | -0.490 |
| Q1 '25 | 63,000 | 31,000 | -31,000 | -6.4M | -5.9M | -0.690 |
| Q4 '24 | 130,000 | 31,000 | -31,000 | -1.9M | -1.9M | -0.557 |
| Q3 '24 | 0 | 31,000 | -31,000 | -11M | -7.1M | -2.850 |
Insider Transactions View All
| KLEMP WALTER V filed to buy 743,607 shares at $0.4. June 23 '25 |
| Foster Jonathan P. filed to buy 287,587 shares at $0.4. June 23 '25 |
| Foster Jonathan P. filed to buy 1,038,320 shares at $0. June 23 '25 |
| KLEMP WALTER V filed to buy 2,409,481 shares at $0. June 23 '25 |
| George Robert E. filed to buy 14,660 shares at $0.7. December 27 '23 |
Similar companies
Read more about Moleculin Biotech (MBRX) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, news mentions, customer reviews & linkedin employees.
FAQ - Moleculin Biotech
The Market Cap of Moleculin Biotech is $22M.
Currently, the price of one share of Moleculin Biotech stock is $2.05.
The MBRX stock price chart above provides a comprehensive visual representation of Moleculin Biotech's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Moleculin Biotech shares. Our platform offers an up-to-date MBRX stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Moleculin Biotech (MBRX) does not offer dividends to its shareholders. Investors interested in Moleculin Biotech should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Moleculin Biotech are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
